Компания Zimmer Biomet приобрела права на безмедикаментозное обезболивающее устройство за 140 млн долларов

Zimmer Biomet acquires rights to medical device for $140 million Subscriber Benefit As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowZimmer Biomet Holdings Inc. has acquired the rights to a drug-free pain relieving device from a California-based biosciences company for up to $140 million. The Warsaw-based medical technology company will pay $70 million upfront and up to $70 million through Dec. 31, 2031, in revenue-based milestone payments to Pacira BioSciences Inc. for its Iovera device, Pacira said in a news release. The FDA-cleared device uses cryoneurolysis to relieve pain. Under cryoneurolysis, cold therapy is applied to a targeted nerve, temporarily interrupting its ability to transmit pain signals. “We believe Zimmer Biomet’s global scale, established expertise commercializing medical devices and commitment to significantly expanding access can unlock the full potential of Iovera to benefit more patients and providers globally,” Pacira BioSciences CEO Frank Lee said in the release. Pacira BioSciences, based in Brisbane, California, markets Iovera to people struggling with osteoarthritis knee pain or who are considering or can’t have knee replacement surgery. Zimmer Biomet is a leading manufacturer of orthopedic devices such as knee replacements. Under the agreement, the two companies will collaborate on advancing the device with an opportunity for Pacira to receive additional compensation. Zimmer Biomet will obtain all rights, titles and interests for the development, manufacture and commercialization of iovera°. The transaction is expected to close in the third quarter of 2026.